DOP67 Comparison of the pharmacokinetics of CT-P13 between Crohn’s Disease and Ulcerative Colitis in biologic-naïve patients; a prospective multi-center observational study of the KASID

Autor:	E S Kim, D I Park, H J Kim, Y J Lee, J S Koo, H Yoon, J H Lee, J W Kim, S J Shin, H W Kim, H S Kim, Y S Park, Y S Kim, T O Kim, J Lee, C H Choi, D S Han, J Chun
Rok vydání:	2021
Předmět:	medicine.medical_specialty Crohn's disease Intention-to-treat analysis business.industry Antidrug antibody Gastroenterology General Medicine medicine.disease Ulcerative colitis Infliximab Therapy naive Pharmacokinetics Internal medicine medicine Observational study business medicine.drug
Zdroj:	Journal of Crohn's and Colitis. 15:S101-S102
ISSN:	1876-4479 1873-9946
Popis:	Background We aimed to compare trough infliximab levels and the development of anti-drug antibody (ADA) for 1 year between Crohn’s disease (CD) and ulcerative colitis (UC) patients who were biologic-naïve and to evaluate their impact on clinical outcomes. Methods This was a prospective, multi-center, observational study. Biologic-naïve patients with moderate to severe CD and UC who started CT-P13 therapy were eligible for the study. The trough drug and ADA levels were measured serially for 1-year after CT-P13 initiation. Clinical outcomes were assessed with intention-to-treat purpose. Results 267 patients who received CT-P13 treatment were enrolled in the study (CD 168, UC 99). The rates of clinical remission (72% vs. 32.3%, p Conclusion CD shows favorable pharmacokinetics of infliximab including high trough drug and low ADA level compared with UC which might be related with better clinical outcomes for 1-year of infliximab.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::74c75ac5d17ea7ef45263c2023313436 https://doi.org/10.1093/ecco-jcc/jjab073.106 Zobrazit plný text záznamu